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INTRODUCTION
Pancreaticobiliary maljunction (PBM) is a con-
genital anomaly defined as a union of the pancre-
atic and biliary ducts outside of the duodenal wall
(1-3). The most important clinical feature is the
frequent association of PBM with biliary cancers.
As the abnormal sphincter muscle cannot function-
ally affect the union, two-way regurgitation (pan-
creatobiliary and biliopancreatic reflux) occurs, re-
sulting in various pathological conditions in the
biliary tract and pancreas (1-3). As the hydropres-
sure in the pancreatic duct is usually higher than
in the bile duct (4), pancreatic juice frequently re-
fluxes into the bile duct through the anomalous
junction, resulting in a high incidence of carcino-
genesis in the biliary tract. From the perspective
of carcinogenesis, the treatment of PBM especially
without bile duct dilatation is controversial ; either
only a cholecystectomy should be performed, in
which case an extrahepatic biliary duct resection
would be unnecessary, or both an extrahepatic bili-
ary duct resection and hepaticojejunostomy should
be undertaken. We herein report a case of hilar
cholangiocarcinoma that occurred 20 years after
cholecystectomy for incidental gallbladder cancer,
with PBM.
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CASE REPORT
A 75-year-old male was referred to our institute
for jaundice and a tumor of the common bile duct.
He was performed a cholecystectomy for cholelithi-
asis 20 years ago at a nearby hospital, and the
histological finding revealed that the gallbladder
had well-differentiated adenocarcinoma in situ. As
further examinations of the biliary tract were not
undertaken, the existence of pancreatobiliary mal-
junction (PBM) was not found at that time. In De-
cember 2010, the patient went to the hospital for
general malaise and was diagnosed with jaundice.
MRCP revealed a tumor in the hepatic portal re-
gion and dilatation of the intrahepatic bile duct. He
was admitted to our institute, and examinations of
the tumor were performed. Abdominal computed
tomography (CT) showed a space occupied with
lesions from the hilar to middle bile duct, with
enhancement and intrahepatic bile duct dilatation
(Figure 1a). Endoscopic retrograde cholangiopan-
creatography (ERCP) revealed stenosis of the hilar
middle bile duct because of the tumor (Figure 1b).
ERCP also showed that the main pancreatic duct
joined the bile duct above the papilla of Vater (classi-
fication of PBM type B, Figure 1b). The diameter
of the common bile duct was 10 mm. In light of the
dilatation caused by the bile duct obstruction result-
ing from the tumor, we diagnosed PBM without
dilatation of the bile duct. We performed endoscopic
retrograde biliary drainage and adenocarcinoma was
detected from bile cytology. We diagnosed hilar
cholangiocarcinoma with PBM. As the abdominal
CT showed swelling of the paraaortic lymph nodes,
we decided that the operation could not be per-
formed. For biliary decompression, an endoscopic
retrograde biliary drainage (ERBD) tube was placed
in the right hepatic duct. However, biliary decom-
pression was not achieved with complete success
due to the tumor in the hepatic portal region. The
patient’s general condition gradually worsened, and
he passed away three months after admission. The
diagnosis from the autopsy was hilar cholangiocar-
cinoma and pancreatobiliary maljunction (Figure 2
a, b). In the specimen obtained from the autopsy,
HE staining showed that the tumor in the hepatic
a b
Figure 2. Specimen of autopsy. (a) total image of the liver. (b) findings of tumor invasion to middle bile duct and pancreaticobiliary
maljunction. Scale bars, 2 cm. Diagnosis was hilar cholangiocarcinoma and pancreatobiliary maljunction.
a b
Figure 1. Findings of liver and bile duct. (a) findings of contrast enhanced CT. There is a tumor from the hepatic portal region to
the middle bile duct with enhancement and intrahepatic bile duct dilatation. (b) findings of ERCP. Tumor causes stenosis of the
hepatic portal regionmiddle bile duct, and the main pancreatic duct joined the bile duct above the papilla of Vater (classification of
PBM type B).
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portal region extended to the middle of the common
bile duct (Figure 3a, b). K-ras and HDAC antibody
staining were positive both in the cancerous part
and non-cancerous part (Figure 4a-d).
DISCUSSION
The pathological condition of PBM is such that
the mixing of phospholipase A2 in pancreatic juice
a b
c d
Figure 4. Immunohistochemical findings for k-ras and HDAC (a,b : k-ras, c,d : HDAC).
(a) cancerous part,100 (b) non cancerous part,200 (intrahepatic bile duct)
(c) cancerous part,100 (d) non cancerous part,200 (intrahepatic bile duct)
a b
Figure 3. HE staining of cancerous part. (a) common bile duct,200 (b) hepatic portal region,200
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and bile will produces lysolecithin, which has se-
vere cell toxicity. Repeated damage to, and resto-
ration of, the biliary epithelium produces a variant
accompanied by cellular atypical change (5), dis-
playing a hyperplasia-dysplasia-carcinoma sequence
(6, 7). From the perspective of carcinogenesis, the
treatment of PBM, especially without bile duct dila-
tation, is controversial ; either only a cholecystec-
tomy should be performed, in which case an extra-
hepatic biliary duct resection would be unnecessary,
or both an extrahepatic biliary duct resection and
hepaticojejunostomy should be performed. It was
reported that the cancer development rates of PBM
in adults with dilatation of bile duct are 13.4% in
the gallbladder, 7.0% in the bile duct, and 1.0% in
the gallbladder+bile duct (8). Those of PBM with-
out dilatation of the bile duct are 37.4% in the gall-
bladder, 3.1% in the bile duct, and 1.8% in the gall-
bladder+bile duct (8). This report has revealed that
PBM has a background of biliary tract carcinogene-
sis regardless of whether it is with or without bile
duct dilatation, and that we should pay attention to
the carcinogenesis of the gallbladder in particular.
Although the carcinogenesis rate of an undilated
bile duct with PBM was the lowest among these
data (3.1%), this rate is 200 times higher than that
seen in usual carcinogenesis of the bile duct in
Japan (9). These facts suggest that biliary diversion
is necessary in the light of carcinogenesis. In terms
of complication of biliary diversion, acute pancrea-
titis, pancreatic fistula, gastrointestinal bleeding and
ileus can occur as early complication. However,
these complications occur with low frequency and
most of them recover by conservative management.
Cholangitis and hepatolithiasis are reported to oc-
cur as late complication, and induced mainly by bile
duct stenosis (10). As these complications can oc-
cur repeatedly, careful, long-term follow-up is im-
portant. About the molecular mechanism of car-
cinogenesis, K-ras are mainly discussed as a gene
abnormality of mucosal epithelium. The genetic mu-
tation of K-ras in the cancerous parts of early gall-
bladder cancer with PBM is seen at a level of 50%,
higher than that of usual early gallbladder cancer
(6%) (11). In terms of bile duct cancer, it was re-
ported that K-ras mutation with PBM was detected
at 60-100% in cancerous parts and at 40% in the non-
cancerous parts with or without dilatation of the
bile duct (12, 13). In our case, since K-ras antibody
staining was positive both in the cancerous and
non-cancerous parts, there could have been a high
potential for carcinogenesis in the bile duct.
From an epigenetic perspective, the status of
histone acetylation, which is controlled by histone
acetyltransferase (HAT) and histone deacetylase
(HDAC), plays an important role in various gene
expressions through the chromatin remodeling. Spe-
cifically, the aberrant activation of HDAC in tumor
cells leads to diverse transcriptional gene repres-
sion, mainly involving the regulation of differentia-
tion, angiogenesis, proliferation, migration, and me-
tastasis (14, 15). Furthermore, it was reported that
HDAC inhibitor decrease the expression of k-ras
(16), and HDAC may influence on k-ras activity in
mechanism of carcinogenesis. In our case, HDAC
staining was positive both in the cancerous and non
cancerous parts. Repeated damage to, and restora-
tion of, the biliary epithelium, can lead to aberrant
activation of HDAC, and relate to the overexpres-
sion of k-ras and potential for carcinogenesis.
In conclusion, we experienced a case of hilar cho-
langiocarcinoma with PBM 20 years after the oc-
currence of gallbladder cancer, and we suggest that
surgery to separate the pancreatic juice and bile
along with a cholecystectomy is needed for PBM,
regardless of the existence or otherwise of bile duct
dilatation.
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